- Home
- SVIV vs NMRA Comparison
SVIV vs NMRA Comparison
Compare SVIV & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | SVIV | NMRA |
|---|---|---|
| Founded | 2025 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 312.2M | 302.0M |
| IPO Year | 2026 | 2023 |
Fundamental Metrics
Financial Performance| Metric | SVIV | NMRA |
|---|---|---|
| Price | $10.18 | $1.04 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 47.1K | ★ 687.0K |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.87 | $0.83 |
| 52 Week High | $10.73 | $3.65 |
Technical Indicators
Market Signals| Indicator | SVIV | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 47.52 | 28.21 |
| Support Level | $9.92 | $0.83 |
| Resistance Level | $10.28 | $1.74 |
| Average True Range (ATR) | 0.03 | 0.09 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 15.00 | 0.96 |
Price Performance
Historical ComparisonAbout SVIV Spring Valley Acquisition Corp. IV Class A Ordinary Shares
Spring Valley Acquisition Corp IV is a blank check company established for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.